A Phase II Study of MRI Based Functional Imaging for the Evaluation of Bone Metastasis in Men With Castrate Resistant Prostate Cancer Receiving XL184
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Cabozantinib (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- 05 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 05 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
- 10 Jun 2017 Biomarkers information updated